Professor Erik Stroes, Amsterdam UMC, The Netherlands, explores the changing landscape in the cardiovascular arena, including growing understanding of the role of elevated Lp(a) as a causal risk factor and its inclusion in routine cardiovascular risk assessment.
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)